Discover
ATYR
aTyr Pharma, Inc.
0.25
1 x 0.28
2 x 0.39
bid
ask
-
0.01
3.56%
2 @ 05:45 AM
0.25 +0.00 (1.54%)
| Ytd | -68.56% | |
| 1y | -74.17% |
0.25
day range
0.26
0.25
52 week range
1.11
| Open | 0.26 | Prev Close | 0.26 | Low | 0.25 | High | 0.26 | Mkt Cap | 24.15M |
| Vol | 1.00M | Avg Vol | 3.23M | EPS | -0.62 | P/E | N/A | Forward P/E | -4.33 |
| Beta | 0.91 | Short Ratio | 2.66 | Inst. Own | 63.15% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 0.44 | 200-d Avg | 0.65 | 1yr Est | 21.29 |
ATYR News
benzinga.com
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease
aTyr Pharma reached FDA alignment on a Phase 3 study for efzofitimod to treat pulmonary sarcoidosis,
benzinga.com
aTyr Pharma Reaches FDA Alignment On Protocol For A Phase 3 Study Of Its Lead Therapeutic Candidate
The planned Phase 3 trial will be a global, randomized, double-blind, placebo-controlled study to ev